Influence of IL28B polymorphisms on response to a lower-than-standard dose peg-IFN-α 2a for genotype 3 chronic hepatitis C in HIV-coinfected patients

PLoS ONE

Volumn 7, Issue 1, 2012, Pages

  López Cortés, Luis F ^a   Ruiz Valderas, Rosa ^a   Jimenez Jimenez, Luis ^a   González Escribano, María F ^a   Torres Cornejo, Almudena ^a   Mata, Rosario ^a   Rivero, Antonio ^b   Pineda, Juan A ^c   Marquez Solero, Manuel ^d   Viciana, Pompeyo ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^b HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^c HOSPITAL UNIVERSITARIO DE VALME   (Spain)

^d HOSPITAL UNIVERSITARIO VIRGEN DE LA VICTORIA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

PEGINTERFERON ALPHA2A; RIBAVIRIN; VIRUS RNA; ALPHA INTERFERON; IL28B PROTEIN, HUMAN; INTERLEUKIN DERIVATIVE; MACROGOL DERIVATIVE; RECOMBINANT PROTEIN;

ADULT; ANEMIA; ANOREXIA; ARTICLE; CLINICAL TRIAL; COUGHING; DEEP VEIN THROMBOSIS; DEPRESSION; DIZZINESS; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; ESOPHAGUS STENOSIS; FATIGUE; FEMALE; FLU LIKE SYNDROME; GENE; GENETIC POLYMORPHISM; GENOTYPE; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IL28B GENE; INJECTION SITE ERYTHEMA; INSOMNIA; IRRITABILITY; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; MYALGIA; NAUSEA AND VOMITING; NERVOUSNESS; NEUROLEPTIC MALIGNANT SYNDROME; NEUTROPENIA; PILOT STUDY; RELAPSE; SIDE EFFECT; STREPTOCOCCUS PNEUMONIA; SUBARACHNOID HEMORRHAGE; SUDDEN DEATH; THROMBOCYTOPENIA; THRUSH; WEIGHT REDUCTION; DOSE RESPONSE; GENETICS; METABOLISM; MIDDLE AGED; SAFETY; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT OUTCOME;

HEPATITIS C VIRUS;

ADULT; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GENOTYPE; HEPATITIS C, CHRONIC; HIV INFECTIONS; HUMANS; INTERFERON-ALPHA; INTERLEUKINS; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; POLYMORPHISM, SINGLE NUCLEOTIDE; RECOMBINANT PROTEINS; RIBAVIRIN; SAFETY; TREATMENT OUTCOME;

EID: 84855311121     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0028115     Document Type: Article

References (30)

1. Sulkowski MS, (2008) Viral hepatitis and HIV coinfection. J Hepatol 48: 353-67.
2. Ghany MG, Strader DB, Thomas DL, Seeff LB; American Association for the Study of Liver Diseases, (2009) Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 49: 1335-1374.
3. Torriani FJ, Rodriguez-Torres M, Rockstroh JK, Lissen E, Gonzalez-Garcia J, et al. (2004) Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med 351: 438-450.
4. Carrat F, Bani-Sadr F, Pol S, Rosenthal E, Lunel-Fabiani F, et al. (2004) Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. JAMA 292: 2839-2848.
5. Laguno M, Murillas J, Blanco JL, Martínez E, Miquel R, et al. (2004) Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for treatment of HIV/HCV co-infected patients AIDS 18: F27-36.
6. Cargnel A, Angeli E, Mainini A, Gubertini G, Giorgi R, et al. (2005) Open, randomized, multicentre italian trial on PEG-IFN plus ribavirin versus PEG-IFN monotherapy for chronic hepatitis C in HIV-coinfected patients on HAART. Antivir Ther 10: 309-317.
7. Crespo M, Sauleda S, Esteban JI, Juarez A, Ribera E, et al. (2007) Peginterferon alpha-2b plus ribavirin vs interferon alpha-2b plus ribavirin for chronic hepatitis C in HIV-coinfected patients. J Viral Hepat 14: 228-238.
8. Berenguer J, González-García J, López-Aldeguer J, Von-Wichmann MA, Quereda C, et al. (2009) Pegylated interferon-α 2a plus ribavirin versus pegylated interferon-α 2b plus ribavirin for the treatment of chronic hepatitis C in HIV-infected patients. J Antimicrob Chemother 63: 1256-1263.
9. Laguno M, Cifuentes C, Murillas J, Veloso S, Larrousse M, et al. (2009) Randomized trial comparing pegylated interferon alpha-2b versus pegylated interferon alpha-2a, both plus ribavirin, to treat chronic hepatitis C in human immunodeficiency virus patients. Hepatology 49: 22-31.
10. Soriano V, Miralles C, Berdún MA, Losada E, Aguirrebengoa K, et al. (2007) Premature treatment discontinuation in HIV/HCV-coinfected patients receiving pegylated interferon plus weight-based ribavirin. Antivir Ther 12: 469-476.
11. Foster GB, Hezode C, Bronowicki JP, Carosi G, Weiland O, et al. (2009) Activity of telaprevir alone or in combination with peginterferon alfa-2a and ribavirin in treatment-naïve genotype 2 and 3 hepatitis C patients. Interim results of study C209. J Hepatol 50: S22.
12. Glue P, Fang JW, Rouzier-Panis R, Raffanel C, Sabo R, et al. (2000) Pegylated interferon-alpha 2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Hepatitis C Intervention Therapy Group. Clin Pharmacol Ther 68: 556-567.
13. Modi M, Fried M, Reindollar R, Rustgi VR, Kenny R, et al. (2000) The pharmacokinetic behavior of pegylated (40 kD) interferon alfa-2a in chronic hepatitis C patients after multiple dosing. Hepatology 32 (Suppl).
14. Lopez-Cortes LF, Valera-Bestard B, Gutierrez-Valencia A, Ruiz-Valderas R, Jimenez L, et al. (2008) Role of pegylated interferon-alpha-2a and ribavirin concentrations in sustained viral response in HCV/HIV-coinfected patients. Clin Pharmacol Ther 84: 573-580.
15. Reddy KR, Wright TL, Pockros PJ, Shiffman M, Everson G, et al. (2001) Efficacy and safety of pegylated (40-kd) interferon alpha-2a compared with interferon alpha-2a in noncirrhotic patients with chronic hepatitis C. Hepatology 33: 433-438.
16. Pockros PJ, Carithers R, Desmond P, Dhumeaux D, Fried MW, et al. (2004) Efficacy and safety of two-dose regimens of peginterferon alpha-2a compared with interferon alpha-2a in chronic hepatitis C: a multicenter, randomized controlled trial. Am J Gastroenterol 99: 1298-1305.
17. Lindsay KL, Trepo C, Heintges T, Shiffman ML, Gordon SC, et al. (2001) A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology 34: 395-403.
18. Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, Matsuura K, et al. (2009) Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 41: 1105-1109.
19. Suppiah V, Moldovan M, Ahlenstiel G, Berg T, Weltman M, et al. (2009) IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet 41: 1100-1104.
20. Scheuer PJ, (1991) Classification of chronic viral hepatitis: a need for reassessment. J Hepatol 13: 372-374.
21. Rodriguez-Torres M, Torriani F, Rockstroh J, Depamphilis J, Carosi G, et al. (2010) Degree of viral decline early in treatment predicts sustained virological response in HCV-HIV coinfected patients treated with peginterferon alfa-2a and ribavirin. HIV Clin Trials 11: 1-10.
22. Abergel A, Hezode C, Leroy V, Barange K, Bronowick JP, et al. (2006) Peginterferon alpha-2b plus ribavirin for treatment of chronic hepatitis C with severe fibrosis: a multicentre randomized controlled trial comparing two doses of peginterferon alpha-2b. J Viral Hepat 13: 811-820.
23. Meyer-Wyss B, Rich P, Egger H, Helbling B, Müllhaupt B, et al. (2006) Comparison of two PEG-interferon alpha-2b doses (1.0 or 1.5 microg/kg) combined with ribavirin in interferon-naïve patients with chronic hepatitis C and up to moderate fibrosis. J Viral Hepat 13: 457-465.
24. Weiland O, Hollander A, Mattsson L, Glaumann H, Lindahl K, et al. (2008) Lower-than-standard dose peg-IFN alfa-2a for chronic hepatitis C caused by genotype 2 and 3 is sufficient when given in combination with weight-based ribavirin. J Viral Hepat 15: 641-645.
25. Martin-Carbonero L, Nuñez M, Mariño A, Alcocer F, Bonet L, et al. (2008) Undetectable hepatitis C virus RNA at week 4 as predictor of sustained virological response in HIV patients with chronic hepatitis C. AIDS 22: 15-21.
26. Ferenci P, Brunner H, Laferl H, Scherzer TM, Maieron A, et al. (2008) A randomized, prospective trial of ribavirin 400 mg/day versus 800 mg/day in combination with peginterferon alfa-2a in hepatitis C virus genotypes 2 and 3. Hepatology 47: 1816-1823.
27. Montes-Cano MA, García-Lozano JR, Abad-Molina C, Romero-Gómez M, Barroso N, et al. (2010) Interleukin-28B genetic variants and hepatitis virus infection by different viral genotypes. Hepatology 52: 33-37.
28. Scherzer TM, Hofer H, Staettermayer AF, Rutter K, Beinhardt S, et al. (2011) Early virologic response and IL28B polymorphisms in patients with chronic hepatitis C genotype 3 treated with peginterferon alfa-2a and ribavirin. J Hepatol 54: 866-871.
29. Pineda JA, Caruz A, Rivero A, Neukam K, Salas I, et al. (2010) Prediction of response to pegylated interferon plus ribavirin by IL28B gene variation in patients coinfected with HIV and hepatitis C virus. Clin Infect Dis 51: 788-795.
30. Sarrazin C, Susser S, Doehring A, Lange CM, Müller T, et al. (2010) Importance of IL28B gene polymorphisms in hepatitis C virus genotype 2 and 3 infected patients. J Hepatol 54: 415-421.